11.58

1.43% -0.18

Keros Therapeutics Inc (KROS)

Overview News Price History Option Chain Financials Why KROS Down? Discussions Forecast

Keros Therapeutics Inc stock is traded at $11.58, with a volume of 79,880. It is down -1.43% in the last 24 hours and up +14.21% over the past month. Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Previous Close:

$11.76

Open:

$11.76

24h Volume:

79,880

Relative Volume:

0.05

Market Cap:

$475.59M

Revenue:

Net Income/Loss:

$-168.05M

P/E Ratio:

-2.2573

EPS:

-5.13

Net Cash Flow:

$-146.15M

1W Performance:

-2.83%

1M Performance:

+14.21%

6M Performance:

-79.66%

1Y Performance:

-82.87%

1-Day Range:

$11.52

$11.94

1-Week Range:

$10.62

$12.04

52-Week Range:

$9.775

$72.37

Keros Therapeutics Inc Stock (KROS) Company Profile

Name

Keros Therapeutics Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

617-314-6297

Address

1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA

Employee

169

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

KROS's Discussions on Twitter

Compare KROS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KROS Keros Therapeutics Inc	11.57	475.59M	0	-168.05M	-146.15M	-5.13
VRTX Vertex Pharmaceuticals Inc	501.63	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	683.33	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	579.08	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.10	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	250.34	26.76B	3.32B	-860.46M	-1.04B	-8.32

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-16-24	Reiterated	Oppenheimer	Outperform
Dec-13-24	Reiterated	H.C. Wainwright	Buy
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy
Jun-25-24	Initiated	Oppenheimer	Outperform
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jul-31-23	Initiated	Wedbush	Outperform
Jul-26-23	Initiated	BofA Securities	Buy
Feb-14-23	Initiated	Cowen	Outperform
Oct-18-22	Initiated	Truist	Buy
Jul-26-22	Initiated	BTIG Research	Buy
Dec-08-20	Reiterated	H.C. Wainwright	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
May-04-20	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
May-04-20	Initiated	SVB Leerink	Outperform

View All

Keros Therapeutics Inc Stock (KROS) Latest News

Mar 08, 2025

Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade - MSN

Mar 08, 2025

Mar 07, 2025

Equities Analysts Set Expectations for KROS Q1 Earnings - MarketBeat

Mar 07, 2025

Mar 06, 2025

Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $42.33 - MarketBeat

Mar 06, 2025

FY2026 Earnings Estimate for KROS Issued By Leerink Partnrs - MarketBeat

Mar 06, 2025

HC Wainwright Issues Optimistic Outlook for KROS Earnings - MarketBeat

Mar 06, 2025

Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $42.33 - Defense World

Mar 06, 2025

Mar 04, 2025

Leerink Partnrs Has Bullish Outlook for KROS FY2026 Earnings - Defense World

Mar 04, 2025

Handelsbanken Fonder AB Boosts Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Mar 04, 2025

Q2 Earnings Forecast for KROS Issued By Leerink Partnrs - MarketBeat

Mar 04, 2025

Mar 03, 2025

HC Wainwright Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price - MarketBeat

Mar 03, 2025

Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $26.00 - MarketBeat

Mar 03, 2025

Keros Therapeutics (NASDAQ:KROS) Releases Earnings Results, Beats Expectations By $0.22 EPS - MarketBeat

Mar 02, 2025

Y Intercept Hong Kong Ltd Raises Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Mar 02, 2025

Mar 01, 2025

Q2 Earnings Estimate for KROS Issued By Leerink Partnrs - Defense World

Mar 01, 2025

Feb 28, 2025

Keros Therapeutics CEO to Speak at Major Conferences - TipRanks

Feb 28, 2025

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - The Manila Times

Feb 28, 2025

When and Where to Hear Keros Therapeutics' Latest Updates: CEO's March Conference Schedule - StockTitan

Feb 28, 2025

Feb 27, 2025

Keros Therapeutics Hold Rating: Uncertainty in KER-065 Development and Cibotercept Safety Concerns - TipRanks

Feb 27, 2025

Keros Therapeutics stock target cut to $40 at H.C. Wainwright By Investing.com - Investing.com South Africa

Feb 27, 2025

Analyst Expectations For Keros Therapeutics's Future - Benzinga

Feb 27, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect - ACCESS Newswire

Feb 27, 2025

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Feb 27, 2025

Feb 26, 2025

Keros Therapeutics Strengthens Financial Position Amid R&D Expansion - TipRanks

Feb 26, 2025